Advertisement

Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 9 10 11 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Spitality–Capacura: investment, 201908 seed financing round from Capacura GmbH + VC Fonds Technologie Berlin 2019-08-27
Spitality–SEVERAL: investment, 201908 seed financing round from Capacura GmbH + VC Fonds Technologie Berlin to advance Krankenhaus.de 2019-08-27
ADC Therapeutics–Freenome: pharmacodiagnostics, 201908– collab developm multiomics biomarker for ADCT-402 treatment in DLBCL 2019-08-26
Univ Florence–Bruker: NMR spectrometer, 201908– supply expected first customer for new 1.2 GHz NMR spectrometer 2019-08-26
Merck (US)–Themis Bioscience: vaccine technology, 201908– collab research + license for use of MV technology platform for vaccine development 2019-08-22
Themis Bioscience–Merck (US): investment, 201908 equity investment €na by MSD as part of vaccine collaboration 2019-08-22
Oncorus–SEVERAL: investment, 201908 financing round Series B $79.5m co-led by Cowen Healthcare Investments + Perceptive Advisors 2019-08-21
Araris Biotech–Redalpine: investment, 201908 seed financing round totalling CHF2.5m incl investor Redalpine 2019-08-20
Araris Biotech–Schroders: investment, 201908 seed financing round totalling CHF2.5m incl investor Schroder Adveq 2019-08-20
Araris Biotech–SEVERAL: investment, 201908 seed financing round CHF2.5m with Redalpine + Schroder Adveq + VI Partners 2019-08-20
Araris Biotech–VI Partners: investment, 201908 seed financing round totalling CHF2.5m incl investor VI Partners 2019-08-20
Bayer–Elanco: investment, 201908– acquisition of Bayer Animal Health business for $5.3b in cash + $2.3b in shares 2019-08-20
Boehringer–Univ Texas: cancer drugs, 201908– collab new virtual r+d center to advance new cancer therapies incl KRAS inhibitors + TRAILR2 agonists 2019-08-12
Curetis–HC Wainwright: investment banking, 201908– supply service Curetis retains HC Wainwright to evaluate all strategic options 2019-08-12
LemnaTec–Nynomic: investment, 201908 acquisition €na of assets of bankrupt LemnaTec Gmbh by Nynomic AG 2019-08-12
Biognosys–SEVERAL: investment, 201908 financing round Series G from existing + new institutional + private investors 2019-08-08
BlueRock Therapeutics–Bayer: investment, 201808– acquisition 100% by acquiring remaining 59.2% for $240m upfront + $360m milestones 2019-08-08
a:head bio–red-stars.com data: investment, 201908– milestone-dependent 7-digit EUR seed investment by red-stars.com data AG in a:head bio AG 2019-08-07
BSSN Software–Merck (DE): investment, 201908 acquisition €na of BSSN Software GmbH by Merck KGaA 2019-08-06
Fosanis–Ananda Ventures: investment, 201908 milllion Euro financing round from Ananda Impact Ventures + VC Fonds Technologie Berlin 2019-08-06
Fosanis–Berlin (govt): investment, 201908 milllion Euro financing round from Ananda Impact Ventures + VC Fonds Technologie Berlin 2019-08-06
Fosanis–SEVERAL: investment, 201908 milllion Euro financing round from Ananda Impact Ventures + VC Fonds Technologie Berlin to advance mika app 2019-08-06
Merck (DE)–BSSN Software: laboratory software, 2014– supply Merck working with BSSN Software 2019-08-06
Platomics–SEVERAL: investment, 201908 investment €7-digit from undisclosed investors 2019-08-06
Cytena–Cellink: investment, 201908 acquisition €30.25m of Cytena GmbH by Cellink AB 2019-08-05
GNA Biosolutions–Bavaria (govt): investment, 201908 financing round Series C totalling $13.5m incl new investor Wachstumsfonds Bayern 2019-08-05
GNA Biosolutions–Bosch: investment, 201908 financing round Series C totalling $13.5m incl existing investor Robert Bosch Venture Capital 2019-08-05
GNA Biosolutions–btov Partners: investment, 201908 financing round Series C totalling $13.5m incl existing investor btov Partners 2019-08-05
GNA Biosolutions–Germany (govt): investment, 201908 financing round Series C totalling $13.5m incl existing investor KfW 2019-08-05
GNA Biosolutions–GreyBird Ventures: investment, 201908 financing round Series C totalling $13.5m incl new investor GreyBird Ventures 2019-08-05
GNA Biosolutions–Mey Capital Matrix: investment, 201908 financing round Series C totalling $13.5m incl existing investor Mey Capital Matrix 2019-08-05
GNA Biosolutions–Occident Group: investment, 201908 financing round Series C totalling $13.5m incl new investor Occident 2019-08-05
GNA Biosolutions–SEVERAL: investment, 201908 financing round Series C $13.5m from new + existing EU + US investors 2019-08-05
GNA Biosolutions–SHS: investment, 201908 financing round Series C totalling $13.5m incl existing investor SHS Gesellschaft für Beteiligungsmanagement 2019-08-05
GNA Biosolutions–UVC Partners: investment, 201908 financing round Series C totalling $13.5m incl existing investor UVC Partners 2019-08-05
Inveox–SEVERAL: investment, 201908 3rd financing round €17m 2019-08-05
Babylon Health–SEVERAL: investment, 201908 financing round $550m from existing + new investors 2019-08-02
Immunic–Germany (govt): grant, 201908–202207 BMBF grant €654k to support German-Japanese research project with InnoMuNIiCH project 2019-08-01
Wellington Partners–Consilium: public relations, 201907 service existent by CSC 2019-07-31
Wellington Partners–EU (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl exisiting investor EIB/EIF 2019-07-31
Wellington Partners–Germany (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl new investor KfW Capital 2019-07-31
Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB 2019-07-31
Wellington Partners–Talanx: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Talanx 2019-07-31
Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company 2019-07-31
Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO 2019-07-31
Quanta Dialysis Technologies–SEVERAL: investment, 201907 financing round Series C £38m led by Swiss family office + btov Partners 2019-07-29
908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al 2019-07-25
Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon 2019-07-25
Merck (DE)–908 Devices: biopharma production technology, 201907– collab 908 + MilliporeSigma + Univ North Carolina on bioreactor process analytics 2019-07-25
EverlyWell–PerkinElmer: consumer diagnostics, 201907– collab + supply CAP lab services immunoassays + genomic tests for US home health test market 2019-07-24
Freenome–Roche: investment, 201907 financing round Series B totalling $160m incl new + co-investor Roche Venture Fund 2019-07-24
Freenome–SEVERAL: investment, 201907 financing round Series B $160m co-led by RA Capital Management + Polaris Partners + incl Roche Venture Fund 2019-07-24
Gilead–Novartis: virostatic agents, 201907– license excl ww for three preclinical antivirals incl upfront payment plus $291m milestones + royalties 2019-07-19
Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC 2019-07-19
Boehringer–Bridge Biotherapeutics: autotaxin inhibitor, 201907– collab + ww license BBT-877 up to €45m upfront/near-term + up to €1.1b + royalties 2019-07-18
MIT–Merck (DE): CRISPR technology, 201907– collab pooling of IP from Merck + Broad Institute for licensing CRISPR for r+d by Broad 2019-07-18
Pyxis Oncology–Agent Capital: investment, 201907 financing round Series A totalling $22m incl co-investor Agent Capital 2019-07-17
Pyxis Oncology–Bayer: investment, 201907 financing round Series A totalling $22m incl lead investor Leaps by Bayer 2019-07-17
Pyxis Oncology–Ipsen: investment, 201907 financing round Series A totalling $22m incl co-investor Ipsen 2019-07-17
Pyxis Oncology–Longwood Fund: investment, 201907 financing round Series A totalling $22m incl co-investor Longwood Fund 2019-07-17
Pyxis Oncology–SEVERAL: investment, 201907 financing round Series A $22m led by Leaps by Bayer 2019-07-17
AM-Pharma–Kurma: investment, 201907 financing round totalling €116m incl existing + co-investor Kurma Partners 2019-07-16
AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners 2019-07-16
Bayer–Evogene: plant genomics, 201907 collaboration amendment to refocus on genome editing target discovery for corn diseases 2019-07-16
Roche–Sosei: GPCR-targeting drugs, 201907– collab multi-target research + licensing up to >$1b Genentech + Sosei Heptares 2019-07-16
Amal Therapeutics–Boehringer: investment, 201907 acquisition of Amal by Boehringer for up to €325m 2019-07-15
Ncardia–Evotec: investment, 201907 acquisition €na of iPSC assets + 17 strong team of bankrupt Ncardia AG in Cologne 2019-07-15
Vasopharm–Bavaria (govt): investment, 201907 financing round totalling €9.5m incl existing + co-investor Bayern Kapital 2019-07-11
Vasopharm–Creathor Ventures: investment, 201907 financing round totalling €9.5m incl new + co-investor Creathor Ventures 2019-07-11
Vasopharm–EF Investments: investment, 201907 financing round totalling €9.5m incl co-lead investor EF Investments 2019-07-11
Vasopharm–HeidelbergCapital: investment, 201907 financing round totalling €9.5m incl existing + co-lead investor HeidelbergCapital Private Equity 2019-07-11
Vasopharm–Hessen (govt): investment, 201907 financing round totalling €9.5m incl existing + co-investor Future Capital 2019-07-11
Vasopharm–Optimum Strategic Communications: public relations, 201907 service existent by Optimum 2019-07-11
Vasopharm–SEVERAL: investment, 201907 financing round €9.5m co-led by HeidelbergCapital Private Equity + EF Investments 2019-07-11
BioNTech–BVCF Management: investment, 201907 financing round Series B totalling $325m incl co-investor BVCF Management 2019-07-09
BioNTech–Fidelity: investment, 201907 financing round Series B totalling $325m incl existing + lead investor Fidelity Management and Research 2019-07-09
BioNTech–Invus Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Invus 2019-07-09
BioNTech–Jebsen Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Jebsen Capital 2019-07-09
BioNTech–Mirae Asset: investment, 201907 financing round Series B totalling $325m incl co-investor Mirae Asset Financial Group 2019-07-09
BioNTech–Platinum Asset Management: investment, 201907 financing round Series B totalling $325m incl co-investor Platinum Asset Management 2019-07-09
BioNTech–Redmile Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Redmile Group 2019-07-09
BioNTech–SEVERAL: investment, 201907 financing round Series B $325m led by Fidelity ./. €87.7m delayed as of 9/19 2019-07-09
BioNTech–Steam Athena Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Steam Athena Capital 2019-07-09
BioNTech–Strüngmann Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investorStrüngmann Family Office 2019-07-09
Revolution Medicines–Nextech: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Nextech Invest 2019-07-09
Breakpoint Therapeutics–Evotec: investment, 201907 first financing round totalling €30m incl co-investor Evotec 2019-07-08
Breakpoint Therapeutics–Medicxi Ventures: investment, 201907 first financing round totalling €30m incl lead investor Medicxi 2019-07-08
Breakpoint Therapeutics–Otsuka: investment, 201907 first financing round totalling €30m incl co-investor Taiho Ventures LLC 2019-07-08
Breakpoint Therapeutics–SEVERAL: investment, 201907 first financing round €30m for spin-out from Evotec led by Medicxi + incl Taiho Ventures + Evotec 2019-07-08
PMOD Technologies–Bruker: investment, 201907 acquisition €na of PMOD Technologies LLC by Bruker 2019-07-08
Nosopharm–Evotec: antibiotics, 201907– collab €na pre-clinical developm of NOSO-502 + 2nd generation odilorhabdin 2019-07-03
Boehringer–Yuhan: GLP1R/FGF21R agonist, 201907– collab + license agreem for FGF21 $40m upfront + $830m milestones + royalties 2019-07-01
Century Therapeutics–Bayer: investment, 201907 financing round totalling $250m commitments incl $215m from Leaps by Bayer 2019-07-01
Century Therapeutics–Fujifilm: investment, 201907 financing round totalling $250m commitments incl co-investor Fujifilm Cellular Dynamics Inc 2019-07-01
Century Therapeutics–SEVERAL: investment, 201907 financing round $250m commitments from Leaps by Bayer + Versant Ventures + Fujifilm CDI 2019-07-01
Century Therapeutics–Versant Ventures: investment, 201907 financing round totalling $250m commitments incl existing + co-investor Versant Ventures 2019-07-01
ExpreS2ion Biotech–ERS Genomics: CRISPR technology, 201907– license non-excl €na for use + commercialisation of products from ERS Genomics 2019-07-01
Merck (DE)–SEVERAL: credit, 201907 three bonds amounting to €2b to finance acquisition of Versum Materials Inc 2019-07-01
next pagenext page 1 2 3 ... 9 10 11 ... 29 30 31  next pagenext page



Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] No Content Marketing 650x80px

» top